A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial

Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has caused outbreaks in various regions of the world. Here the authors present safety and immunogenicity data from a phase 1 trial with the simian adenovirus vectored vaccine ChAdOx1 Chik, showing induction of neutralizing antibodie...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pedro M. Folegatti, Kate Harrison, Lorena Preciado-Llanes, Fernando Ramos Lopez, Mustapha Bittaye, Young Chan Kim, Amy Flaxman, Duncan Bellamy, Rebecca Makinson, Jonathan Sheridan, Sasha R. Azar, Rafael Kroon Campos, Mark Tilley, Nguyen Tran, Daniel Jenkin, Ian Poulton, Alison Lawrie, Rachel Roberts, Eleanor Berrie, Shannan L. Rossi, Adrian Hill, Katie J. Ewer, Arturo Reyes-Sandoval
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/e71818edfedb43ec92d1c8c53528e12d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e71818edfedb43ec92d1c8c53528e12d
record_format dspace
spelling oai:doaj.org-article:e71818edfedb43ec92d1c8c53528e12d2021-12-02T16:24:57ZA single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial10.1038/s41467-021-24906-y2041-1723https://doaj.org/article/e71818edfedb43ec92d1c8c53528e12d2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-24906-yhttps://doaj.org/toc/2041-1723Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has caused outbreaks in various regions of the world. Here the authors present safety and immunogenicity data from a phase 1 trial with the simian adenovirus vectored vaccine ChAdOx1 Chik, showing induction of neutralizing antibodies to four CHIKV lineages.Pedro M. FolegattiKate HarrisonLorena Preciado-LlanesFernando Ramos LopezMustapha BittayeYoung Chan KimAmy FlaxmanDuncan BellamyRebecca MakinsonJonathan SheridanSasha R. AzarRafael Kroon CamposMark TilleyNguyen TranDaniel JenkinIan PoultonAlison LawrieRachel RobertsEleanor BerrieShannan L. RossiAdrian HillKatie J. EwerArturo Reyes-SandovalNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Pedro M. Folegatti
Kate Harrison
Lorena Preciado-Llanes
Fernando Ramos Lopez
Mustapha Bittaye
Young Chan Kim
Amy Flaxman
Duncan Bellamy
Rebecca Makinson
Jonathan Sheridan
Sasha R. Azar
Rafael Kroon Campos
Mark Tilley
Nguyen Tran
Daniel Jenkin
Ian Poulton
Alison Lawrie
Rachel Roberts
Eleanor Berrie
Shannan L. Rossi
Adrian Hill
Katie J. Ewer
Arturo Reyes-Sandoval
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
description Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has caused outbreaks in various regions of the world. Here the authors present safety and immunogenicity data from a phase 1 trial with the simian adenovirus vectored vaccine ChAdOx1 Chik, showing induction of neutralizing antibodies to four CHIKV lineages.
format article
author Pedro M. Folegatti
Kate Harrison
Lorena Preciado-Llanes
Fernando Ramos Lopez
Mustapha Bittaye
Young Chan Kim
Amy Flaxman
Duncan Bellamy
Rebecca Makinson
Jonathan Sheridan
Sasha R. Azar
Rafael Kroon Campos
Mark Tilley
Nguyen Tran
Daniel Jenkin
Ian Poulton
Alison Lawrie
Rachel Roberts
Eleanor Berrie
Shannan L. Rossi
Adrian Hill
Katie J. Ewer
Arturo Reyes-Sandoval
author_facet Pedro M. Folegatti
Kate Harrison
Lorena Preciado-Llanes
Fernando Ramos Lopez
Mustapha Bittaye
Young Chan Kim
Amy Flaxman
Duncan Bellamy
Rebecca Makinson
Jonathan Sheridan
Sasha R. Azar
Rafael Kroon Campos
Mark Tilley
Nguyen Tran
Daniel Jenkin
Ian Poulton
Alison Lawrie
Rachel Roberts
Eleanor Berrie
Shannan L. Rossi
Adrian Hill
Katie J. Ewer
Arturo Reyes-Sandoval
author_sort Pedro M. Folegatti
title A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
title_short A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
title_full A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
title_fullStr A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
title_full_unstemmed A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
title_sort single dose of chadox1 chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/e71818edfedb43ec92d1c8c53528e12d
work_keys_str_mv AT pedromfolegatti asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT kateharrison asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT lorenapreciadollanes asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT fernandoramoslopez asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT mustaphabittaye asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT youngchankim asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT amyflaxman asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT duncanbellamy asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rebeccamakinson asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT jonathansheridan asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT sasharazar asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rafaelkrooncampos asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT marktilley asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT nguyentran asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT danieljenkin asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT ianpoulton asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT alisonlawrie asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rachelroberts asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT eleanorberrie asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT shannanlrossi asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT adrianhill asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT katiejewer asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT arturoreyessandoval asingledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT pedromfolegatti singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT kateharrison singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT lorenapreciadollanes singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT fernandoramoslopez singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT mustaphabittaye singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT youngchankim singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT amyflaxman singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT duncanbellamy singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rebeccamakinson singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT jonathansheridan singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT sasharazar singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rafaelkrooncampos singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT marktilley singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT nguyentran singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT danieljenkin singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT ianpoulton singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT alisonlawrie singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT rachelroberts singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT eleanorberrie singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT shannanlrossi singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT adrianhill singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT katiejewer singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
AT arturoreyessandoval singledoseofchadox1chikvaccineinducesneutralizingantibodiesagainstfourchikungunyaviruslineagesinaphase1clinicaltrial
_version_ 1718384087559831552

Ejemplares similares